Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
Theodoros Karantanos,1 Ioannis Politikos,2 Vassiliki A Boussiotis3–5 1General Internal Medicine Section, Boston Medical Center, Boston University School of Medicine, Boston, MA, 2Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,...
Enregistré dans:
Auteurs principaux: | Karantanos T, Politikos I, Boussiotis VA |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a78f0932b2e542a597ae09502b0e554a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
par: Lapuz C, et autres
Publié: (2018) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
par: Bhutani D, et autres
Publié: (2017) -
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
par: Oncale MB, et autres
Publié: (2017) -
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
par: Illidge T, et autres
Publié: (2012) -
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
par: Megías-Vericat JE, et autres
Publié: (2019)